Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 0.21 GBp
Change Today 0.00 / 0.00%
Volume 7.9M
As of 8:35 AM 05/6/15 All times are local (Market data is delayed by at least 15 minutes).

valirx plc (VAL) Snapshot

Open
0.21 GBp
Previous Close
0.21 GBp
Day High
0.21 GBp
Day Low
0.21 GBp
52 Week High
09/24/14 - 0.52 GBp
52 Week Low
04/22/15 - 0.18 GBp
Market Cap
7.9M
Average Volume 10 Days
33.3M
EPS TTM
-0.0010 GBp
Shares Outstanding
3.8B
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VALIRX PLC (VAL)

Related News

No related news articles were found.

valirx plc (VAL) Related Businessweek News

No Related Businessweek News Found

valirx plc (VAL) Details

ValiRx Plc, an investment holding company, engages in the research and development of technologies and products in oncology therapeutics and diagnostics in the United Kingdom. The company operates in two segments, Drug Development and Sale of Self-Test Drug Kits. Its proprietary GeneICE technology enables selective silencing of rebellious genes, which cause cancers, inflammatory conditions, and Alzheimer’s and autoimmune diseases. The company’s lead drug candidates in late stage pre-clinical development include VAL101, a novel therapeutic based on GeneICE platform that acts to target and switch off the Bcl-2 gene, a protein that inhibits the process of apoptosis; and VAL201, a novel peptide for the treatment of hormone refractory prostate cancer, and other indications of hormone induced unregulated growth, including endometriosis. It is also developing ValiFinn BioMarkers that are diagnostic markers of inhibition of signaling pathways, which are target sites for novel drugs to treat cancer; and predictive markers of disease progression, as well as VAL401, a clinical drug to treat patients with lung cancer. The company was incorporated in 2000 and is based in London, the United Kingdom.

12 Employees
Last Reported Date: 04/23/15
Founded in 2000

valirx plc (VAL) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: 182.5K GBP
Chief Financial Officer, Director and Member ...
Total Annual Compensation: 74.0K GBP
Chief Operating Officer and Director
Total Annual Compensation: 118.0K GBP
Compensation as of Fiscal Year 2013.

valirx plc (VAL) Key Developments

ValiRx plc Proposes Amendment to the Articles

ValiRx plc proposed to the AGM to be held on May 15, 2015 amendment to the articles.

ValiRx plc Reports Consolidated Earnings Results for the Year Ended December 31, 2014

ValiRx Plc reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported revenue of £87,558 compared to £124,868 a year ago. Operating loss was £3,138,131 compared to £2,911,087 last year. Loss before taxation was £3,641,335 compared to £2,905,715 last year. Loss and total comprehensive income attributable to owners of the parent was £3,160,031 or 0.08 pence per basic and diluted share compared to £2,702,258 or 0.15 pence per basic and diluted share last year. Net cash outflows from operating activities were £3,316,712 compared to £2,232,552 last year. Payments to acquire intangible assets were £273,846 compared to £132,135 last year. Payments to acquire tangible assets were £1,408 compared to £1,922 last year.

Valirx Plc Receives Patent Approval for Lead Therapeutic Compound VAL201

ValiRx Plc announced that it has received patent approval by the UK Patent Office regarding its lead therapeutic compound VAL201 for a further indication in endometriosis or hormone induced abnormal cell growth in women. Based on results in endometrial models, VAL201 has been shown to reduce abnormal endometrial growth, whilst leaving other hormone-induced activities working normally. Endometriosis is a gynaecological medical condition in which cells from the lining of the uterus (endometrium) appear and flourish outside the uterine cavity, most commonly on the ovaries. The uterine cavity is lined by endometrial cells, which are under the influence of female hormones.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VAL:LN 0.21 GBp 0.00

VAL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for VAL.
View Industry Companies
 

Industry Analysis

VAL

Industry Average

Valuation VAL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 111.2x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 87.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VALIRX PLC, please visit www.valirx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.